
David R Anderson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7585665/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer. Thrombosis and Haemostasis, 2000, 83, 416-420.	1.8	1,417
2	Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis. New England Journal of Medicine, 2003, 349, 1227-1235.	13.9	1,329
3	Excluding Pulmonary Embolism at the Bedside without Diagnostic Imaging: Management of Patients with Suspected Pulmonary Embolism Presenting to the Emergency Department by Using a Simple Clinical Model and <scp>d</scp> -dimer. Annals of Internal Medicine, 2001, 135, 98.	2.0	1,198
4	A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis. New England Journal of Medicine, 1996, 334, 677-681.	13.9	1,157
5	Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet, The, 1997, 350, 1795-1798.	6.3	1,093
6	A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism. New England Journal of Medicine, 1999, 340, 901-907.	13.9	1,052
7	Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range. Chest, 2001, 119, 8S-21S.	0.4	862
8	Oral Anticoagulants. Chest, 1998, 114, 445S-469S.	0.4	856
9	A Comparison of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with the Antiphospholipid Antibody Syndrome. New England Journal of Medicine, 2003, 349, 1133-1138.	13.9	845
10	Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine, 2003, 349, 631-639.	13.9	728
11	Managing Oral Anticoagulant Therapy. Chest, 2001, 119, 22S-38S.	0.4	525
12	Computed Tomographic Pulmonary Angiography vs Ventilation-Perfusion Lung Scanning in Patients With Suspected Pulmonary Embolism. JAMA - Journal of the American Medical Association, 2007, 298, 2743.	3.8	488
13	Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet, The, 2014, 383, 880-888.	6.3	425
14	Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study Commentary: Varied preferences reflect the reality of clinical practice. BMJ: British Medical Journal, 2001, 323, 1218-1218.	2.4	363
15	Randomized Placebo-Controlled Study of Low-Dose Warfarin for the Prevention of Central Venous Catheter–Associated Thrombosis in Patients With Cancer. Journal of Clinical Oncology, 2005, 23, 4063-4069.	0.8	304
16	American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Advances, 2019, 3, 3898-3944.	2.5	299
17	Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. New England Journal of Medicine, 2018, 378, 699-707.	13.9	294
18	Subcutaneous Heparin Versus Low-Molecular-Weight Heparin as Thromboprophylaxis in Patients Undergoing Colorectal Surgery. Annals of Surgery, 2001, 233, 438-444.	2.1	216

#	Article	IF	CITATIONS
19	Deep Venous Thrombosis: Recent Advances and Optimal Investigation with US. Radiology, 1999, 211, 9-24.	3.6	209
20	Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together with Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism. Annals of Internal Medicine, 2003, 138, 714.	2.0	193
21	Functional and Exercise Limitations After a First Episode of Pulmonary Embolism. Chest, 2017, 151, 1058-1068.	0.4	192
22	Use of Statins and the Subsequent Development of Deep Vein Thrombosis. Archives of Internal Medicine, 2001, 161, 1405.	4.3	178
23	Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty. Annals of Internal Medicine, 2013, 158, 800.	2.0	176
24	Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ: British Medical Journal, 2017, 356, j1065.	2.4	174
25	Guidelines on the Use of Intravenous Immune Globulin for Hematologic Conditions. Transfusion Medicine Reviews, 2007, 21, S9-S56.	0.9	169
26	An Evaluation of <scp>d</scp> -Dimer in the Diagnosis of Pulmonary Embolism. Annals of Internal Medicine, 2006, 144, 812.	2.0	159
27	A Randomized Trial Comparing 2 Low-Molecular-Weight Heparins for the Outpatient Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Archives of Internal Medicine, 2005, 165, 733.	4.3	156
28	Efficacy and Cost of Low-Molecular-Weight Heparin Compared with Standard Heparin for the Prevention of Deep Vein Thrombosis after Total Hip Arthroplasty. Annals of Internal Medicine, 1993, 119, 1105.	2.0	133
29	Prophylaxis Against Deep Vein Thrombosis in Critically Ill Patients With Severe Renal Insufficiency With the Low-Molecular-Weight Heparin Dalteparin <subtitle>An Assessment of Safety and Pharmacodynamics: The DIRECT Study</subtitle> . Archives of Internal Medicine, 2008, 168, 1805.	4.3	133
30	Oral Vitamin K Versus Placebo to Correct Excessive Anticoagulation in Patients Receiving Warfarin. Annals of Internal Medicine, 2009, 150, 293.	2.0	132
31	A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood, 2012, 119, 1356-1362.	0.6	111
32	Evaluation of a Portable Prothrombin Time Monitor for Home Use by Patients Who Require Long-term Oral Anticoagulant Therapy. Archives of Internal Medicine, 1993, 153, 1441.	4.3	109
33	Quality of Life, Dyspnea, and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort Study. American Journal of Medicine, 2017, 130, 990.e9-990.e21.	0.6	107
34	Six-month exercise training program to treat post-thrombotic syndrome: a randomized controlled two-centre trial. Cmaj, 2011, 183, 37-44.	0.9	105
35	Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood, 2008, 112, 4432-4436.	0.6	103
36	Application of a Diagnostic Clinical Model for the Management of Hospitalized Patients with Suspected Deep-vein Thrombosis. Thrombosis and Haemostasis, 1999, 81, 493-497.	1.8	98

#	Article	IF	CITATIONS
37	Pathogen inactivation: making decisions about new technologies. Transfusion, 2007, 47, 2338-2347.	0.8	98
38	The Use of Immunoglobulin Therapy for Patients Undergoing Solid Organ Transplantation: An Evidence-Based Practice Guideline. Transfusion Medicine Reviews, 2010, 24, S7-S27.	0.9	96
39	SimpliRED D-dimer can reduce the diagnostic tests in suspected deep vein thrombosis. Lancet, The, 1998, 351, 1405-1406.	6.3	95
40	Thrombosis in the Emergency Department. Archives of Internal Medicine, 1999, 159, 477.	4.3	93
41	The Use of Immunoglobulin Therapy for Patients With Primary Immune Deficiency: An Evidence-Based Practice Guideline. Transfusion Medicine Reviews, 2010, 24, S28-S50.	0.9	93
42	Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial. Cmaj, 2005, 173, 496-501.	0.9	80
43	Use of spiral computed tomography contrast angiography and ultrasonography to exclude the diagnosis of pulmonary embolism in the emergency department. Journal of Emergency Medicine, 2005, 29, 399-404.	0.3	80
44	Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. British Journal of Haematology, 2005, 129, 79-86.	1.2	77
45	Limitations of Impedance Plethysmography in the Diagnosis of Clinically Suspected Deep-Vein Thrombosis. Annals of Internal Medicine, 1993, 118, 25.	2.0	76
46	Assessment of Deep Vein Thrombosis or Pulmonary Embolism by the Combined Use of Clinical Model and Noninvasive Diagnostic Tests. Seminars in Thrombosis and Hemostasis, 2000, 26, 643-656.	1.5	76
47	Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. American Journal of Medicine, 2001, 111, 270-273.	0.6	76
48	Catheter-Associated Thrombosis in Patients With Malignancy. Journal of Clinical Oncology, 2009, 27, 4858-4864.	0.8	75
49	Management of patients with suspected deep vein thrombosis in the Emergency Department: Combining use of a clinical diagnosis model with D-dimer testing. Journal of Emergency Medicine, 2000, 19, 225-230.	0.3	71
50	Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. Journal of Critical Care, 2005, 20, 364-372.	1.0	70
51	Subcutaneous Heparin Therapy during Pregnancy: a Need for Concern at the Time of Delivery. Thrombosis and Haemostasis, 1991, 65, 248-250.	1.8	69
52	Transient global amnesia associated with acute heparin-induced thrombocytopenia. American Journal of Medicine, 1994, 97, 489-491.	0.6	61
53	Alloimmune Thrombocytopenia after Organ Transplantation. New England Journal of Medicine, 1999, 341, 1504-1507.	13.9	60
54	The diagnosis and treatment of venous thromboembolism. Hematology American Society of Hematology Education Program, 2013, 2013, 457-463.	0.9	60

#	Article	IF	CITATIONS
55	Comparison of the Accuracy of Impedance Plethysmography and Compression Ultrasonography in Outpatients with Clinically Suspected Deep Vein Thrombosis. Thrombosis and Haemostasis, 1995, 74, 1423-1427.	1.8	60
56	A comparison of three rapid D-dimer methods for the diagnosis of venous thromboembolism. British Journal of Haematology, 2001, 115, 140-144.	1.2	59
57	Effectiveness of compression stockings to prevent the post-thrombotic syndrome (The SOX Trial and) Tj ETQq1 1 21.	0.784314 0.7	4 rgBT /Over 59
58	Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Thrombosis and Haemostasis, 2010, 104, 498-503.	1.8	59
59	Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients. Thrombosis Research, 2008, 123, 177-183.	0.8	58
60	Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. Cmaj, 2003, 169, 293-8.	0.9	56
61	Graduated compression stockings to treat acute leg pain associated with proximal DVT. Thrombosis and Haemostasis, 2014, 112, 1137-1141.	1.8	48
62	Effect of Patient Weight on the Anticoagulant Response to Adjusted Therapeutic Dosage of Low-Molecular- Weight Heparin for the Treatment ofVenous Thromboembolism. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2001, 31, 42-48.	0.5	46
63	Inter-observer reliability of measures to assess the post-thrombotic syndrome. Thrombosis and Haemostasis, 2008, 100, 164-166.	1.8	46
64	Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment: the 'Perception of Anticoagulant Treatment Questionnaire' (PACT-Q©). Health and Quality of Life Outcomes, 2009, 7, 9.	1.0	44
65	Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. Annals of Hematology, 2016, 95, 1077-1087.	0.8	43
66	Treatment of Guillain-Barr� syndrome: A cost-effectiveness analysis. Journal of Clinical Apheresis, 1999, 14, 107-113.	0.7	38
67	Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. BMJ, The, 2021, 373, n1205.	3.0	38
68	Evidence-Based Guidelines on the Use of Intravenous Immune Globulin for Hematologic and Neurologic Conditions. Transfusion Medicine Reviews, 2007, 21, S3-S8.	0.9	37
69	Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group. Transfusion, 2007, 47, 2072-2080.	0.8	37
70	D-dimer for the diagnosis of venous thromboembolism. Current Opinion in Hematology, 2000, 7, 296-301.	1.2	36
71	Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Thrombosis and Haemostasis, 2010, 104, 118-121.	1.8	34
72	Computerized tomographic pulmonary angiography versus ventilation perfusion lung scanning for the diagnosis of pulmonary embolism. Current Opinion in Pulmonary Medicine, 2009, 15, 425-429.	1.2	32

#	Article	IF	CITATIONS
73	The Cost-Effectiveness of Extended-Duration Antithrombotic Prophylaxis After Total Hip Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2007, 89, 819-828.	1.4	30
74	COMPARISON OF A NOMOGRAMAND PHYSICIAN-ADJUSTED DOSAGE OF WARFARIN FOR PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS AFTER ARTHROPLASTY. Journal of Bone and Joint Surgery - Series A, 2002, 84, 1992-1997.	1.4	29
75	Cost Effectiveness of the Prevention and Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Pharmacoeconomics, 1997, 12, 17-29.	1.7	28
76	Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2015, 3, 347-353.e1.	0.9	28
77	Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. Thrombosis Research, 2018, 162, 104-109.	0.8	27
78	Improvements in the Diagnostic Approach for Patients with Suspected Deep Vein Thrombosis or Pulmonary Embolism. Thrombosis and Haemostasis, 1999, 82, 878-886.	1.8	27
79	Venous protocols, techniques, and interpretations of the upper and lower extremities. Radiologic Clinics of North America, 2004, 42, 279-296.	0.9	26
80	The impact of warfarin use on clinical outcomes in atrial fibrillation: A population-based study. Canadian Journal of Cardiology, 2007, 23, 457-461.	0.8	26
81	Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. Blood Advances, 2020, 4, 2351-2365.	2.5	26
82	Diagnosis of deep-vein thrombosis in the year 2000. Current Opinion in Pulmonary Medicine, 2000, 6, 309-313.	1.2	25
83	Dalteparin Vs Low-Dose Unfractionated Heparin for Prophylaxis Against Clinically Evident Venous Thromboembolism in Acute Traumatic Spinal Cord Injury: A Retrospective Cohort Study. Journal of Spinal Cord Medicine, 2008, 31, 379-387.	0.7	25
84	An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. Journal of Clinical Pharmacology, 2014, 54, 901-909.	1.0	24
85	Serial imaging after pulmonary embolism and correlation with functional limitation at 12Âmonths: Results of the ELOPE Study. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 670-677.	1.0	23
86	The diagnosis of deep venous thrombosis and pulmonary embolism in medical-surgical intensive care unit patients. Journal of Critical Care, 2005, 20, 314-319.	1.0	21
87	Septic arthritis due toStreptobacillus moniliformis. Arthritis and Rheumatism, 1987, 30, 229-230.	6.7	17
88	Bridging the Gap between Primary and Secondary Care: Use of a Clinical Pathway for the Investigation and Management of Deep Vein Thrombosis. Journal of Health Services Research and Policy, 2008, 13, 15-19.	0.8	17
89	The Cost-Effectiveness of Extended-Duration Antithrombotic Prophylaxis After Total Hip Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2007, 89, 819-828.	1.4	17
90	PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT): A Pilot Study Blood, 2004, 104, 1784-1784.	0.6	14

#	Article	IF	CITATIONS
91	Warfarin-Induced Skin Necrosis in 2 Patients with Protein S Deficiency: Successful Reinstatement of Warfarin Therapy. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1992, 22, 124-128.	0.5	12
92	A multicenter prospective study of risk factors and treatment of unusual site thrombosis. Thrombosis Research, 2016, 144, 100-105.	0.8	12
93	Longâ€ŧerm risk of recurrent venous thromboembolism after a first contraceptiveâ€related event: Data from REVERSE cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 1526-1532.	1.9	12
94	A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643]. BMC Cardiovascular Disorders, 2004, 4, 5.	0.7	11
95	Skeletal Muscle Ventricles: Update After 18 Months in Circulation. Artificial Organs, 1991, 15, 350-354.	1.0	11
96	The Use of Leg Venous Ultrasonography for the Diagnosis of Pulmonary Embolism. Seminars in Nuclear Medicine, 2008, 38, 412-417.	2.5	11
97	Aspirin Versus Low-Molecular-Weight Heparin After Total Hip Arthroplasty. Annals of Internal Medicine, 2013, 159, 502.	2.0	11
98	A systematic review of economic analyses of low-molecular-weight heparin for the treatment of venous thromboembolism. Thrombosis Research, 2003, 112, 193-201.	0.8	10
99	How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. Blood Advances, 2021, 5, 4721-4726.	2.5	10
100	Population-based evaluation of the management of antithrombotic therapy for atrial fibrillation. Canadian Journal of Cardiology, 2005, 21, 257-66.	0.8	10
101	Direct Oral Anticoagulants and Vitamin K Antagonists for Treatment of Deep Venous Thrombosis and Pulmonary Embolism in the Outpatient Setting: Comparative Economic Evaluation. Canadian Journal of Hospital Pharmacy, 2017, 70, 188-199.	0.1	9
102	Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials. BMJ, The, 2022, 376, e066785.	3.0	9
103	Guidelines for the Use of Intravenous Immune Globulin for Hematologic and Neurologic Conditions. Transfusion Medicine Reviews, 2007, 21, S1-S2.	0.9	8
104	Psychological impact of thrombophilia testing in asymptomatic family members. Thrombosis Research, 2011, 128, 530-535.	0.8	8
105	Pharmacologic thromboprophylaxis in adult patients undergoing neurosurgical interventions for preventing venous thromboembolism. Blood Advances, 2020, 4, 2798-2809.	2.5	7
106	"Post-Pulmonary Embolism Syndrome" after a First Episode of PE: Results of the E.L.O.P.E. Study. Blood, 2015, 126, 650-650.	0.6	7
107	Diagnosing deep vein thrombosis in cancer patients with suspected symptoms: An individual participant data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 2245-2252.	1.9	6
108	A Pilot Study to Assess the Feasibility of a Multicenter Cluster Randomized Trial for the Management of Asymptomatic Persons with a Thrombophilia. Journal of Genetic Counseling, 2009, 18, 475-482.	0.9	5

#	Article	IF	CITATIONS
109	Inadvertent Overdose of Low-Molecular- Weight Heparin in an Elderly Patient with Deep Vein Thrombosis and Acute Kidney Injury. Canadian Journal of Hospital Pharmacy, 2016, 69, 320-2.	0.1	4
110	N-terminal of prohormone brain natriuretic peptide predicts functional limitation one year following pulmonary embolism: Results from the ELOPE study. Thrombosis Research, 2017, 153, 47-49.	0.8	4
111	A Pilot Study of Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombois of the Upper Extremity (UEDVT) Blood, 2006, 108, 878-878.	0.6	4
112	Inflammation Markers and The Risk Of Post Thrombotic Syndrome: Results From The Bio-Sox Study. Blood, 2013, 122, 36-36.	0.6	3
113	Inter-observer reliability of the HERDOO2 clinical decision rule. Thrombosis Research, 2016, 141, 136-138.	0.8	2
114	Venous Thromboembolism Prophylaxis after Hip or Knee Arthroplasty. New England Journal of Medicine, 2018, 378, 1848-1849.	13.9	2
115	Predictors Of The Post-Thrombotic Syndrome In a Large Cohort Of Patients With Proximal DVT: Secondary Analysis Of The Sox Trial. Blood, 2013, 122, 460-460.	0.6	2
116	Post-Thrombotic Syndrome and Functional Disability in Patients with Upper Extremity Deep Vein Thrombosis: A Prospective Cohort Study. Blood, 2016, 128, 417-417.	0.6	2
117	Modern Approach to Diagnosis in Patients with Suspected Deep Vein Thrombosis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1999, 29, 10-20.	0.5	1
118	Influence of Warfarin on Symptoms of Fatigue: Findings of a Randomized Trial. Annals of Pharmacotherapy, 2005, 39, 840-842.	0.9	1
119	Dyspnea, Quality of Life and Walking Capacity during 1 Year Follow-up after a First Episode of Pulmonary Embolism: Results of the E.L.O.P.E. Study. Blood, 2015, 126, 750-750.	0.6	1
120	A modeling approach to derive baseline risk estimates for GRADE recommendations: Concepts, development, and results of its application to the American Society of Hematology 2019 guidelines on prevention of venous thromboembolism in surgical hospitalized patients. Journal of Clinical Epidemiology, 2021, 140, 69-78.	2.4	0
121	Survey of Red Blood Cell Transfusion Practices in Medically Ill Patients Blood, 2005, 106, 4181-4181.	0.6	0
122	Predictors of Red Cell Transfusion in Medically III Patients Blood, 2005, 106, 4180-4180.	0.6	0
123	Comparison of the Villalta Post Thrombotic Syndrome (PTS) Score in the Ipsilateral Versus Contralateral Leg After a First Unprovoked Deep Vein Thrombosis (DVT): Results From the REVERSE Study. Blood, 2011, 118, 1236-1236.	0.6	0
124	Frequency and Predictors of Post-Thrombotic Syndrome in Patients with a First, Unprovoked Deep Vein Thrombosis and No Prior Primary Venous Insufficiency: Results From the REVERSE Cohort Study,. Blood, 2011, 118, 3332-3332.	0.6	0
125	Family History of Venous Thromboembolism (VTE) and the Risk of VTE Recurrence in Patients with a First Unprovoked VTE: A Multicenter Prospective Cohort Study. Blood, 2011, 118, 2299-2299.	0.6	0
126	The Effectiveness Of 30-40 Mm Hg Compression Stockings To Treat Acute Leg Pain Associated With Proximal Deep Vein Thrombosis: Results From The Sox Randomized Controlled Trial. Blood, 2013, 122, 1126-1126.	0.6	0

#	Article	IF	CITATIONS
127	A Paired Comparison of the Accuracy of Two Impedance Plethysmographs. Thrombosis and Haemostasis, 1997, 77, 805-806.	1.8	0
128	Brain Natriuretic Peptide, Troponin and D-Dimer Levels in Relation to Long-Term Functional Outcome after a First Episode of Pulmonary Embolism: Results from the E.L.O.P.E. Study. Blood, 2015, 126, 649-649.	0.6	0
129	Economic Evaluation of the Direct Oral Anticoagulants Compared to Vitamin K Antagonists in the Treatment of Deep Venous Thrombosis and Pulmonary Embolism in the Outpatient Setting: Analysis from the Queen Elizabeth II Health Sciences Centre in Halifax, Nova Scotia. Blood, 2016, 128, 3528-3528.	0.6	0